CRD 3874
Alternative Names: CRD-3874; CRD3874-SILatest Information Update: 17 Jun 2025
At a glance
- Originator Curadev Pharma
- Developer Curadev Pharma; University of Maryland, Baltimore
- Class Antineoplastics; Small molecules
- Mechanism of Action STING1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia; Merkel cell carcinoma; Sarcoma
- Preclinical Solid tumours
Most Recent Events
- 10 Jun 2025 Curadev Pharma and Memorial Sloan Kettering Cancer Center (MSK) expand there collaboration through the MSK Therapeutics Accelerator program to advance the development of CRD3874 SI
- 25 Apr 2025 Pharmacodynamics data from a preclinical trial in Acute myeloid leukaemia presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 26 Aug 2024 Phase-I clinical trials in Acute myeloid leukaemia in USA (IV) (NCT06626633)